Why GOP Complaints about Pharma Price-Gouging of Vets is a Hypocritical Smokescreen

by Nomad

One Republican complaints against a drugmaker's price-gouging may be applaudable. As long as you have only half of the facts. 

In yet another example of mainstream media failing to properly inform the public, we can point to CNN and its posting of US Rep. Jeff Miller's op-ed piece. The article demonstrates how, when critical information is left out of a story, the news becomes nothing less than a lie.

The subject of Miller's piece is price-gouging by pharma companies, particularly when it comes to medication for veterans. The company in question, Gilead Sciences, has been scrutinized on several occasions in this blog. (here, here and here)

In his article, the Congressman for Florida's First district writes:

If not for the service and sacrifice of those who have worn the uniform, the United States would not be the extraordinary place it is today. Unfortunately, this concept seems lost on the people at drugmaker Gilead Sciences.

Whenever we try to qualify patients by who "deserves" life-saving treatments more, we run into ethical questions. It is all in keeping with Republican efforts to be percieved as actually caring about veterans.
The record tells a different story. In fact, the GOP has a fairly dismal record when it comes to veterans. Last year, the House Appropriations removed more than $1.4 billion from President Obama’s proposed 2016 budget. As one source notes:

As a result of the cuts, it was estimated that 70,000 fewer veterans would be able to receive needed care.

How Three Asian Nations are Beating Outrageous Price-Gouging by American Pharmas

by Nomad

Some have started to question the exorbitant prices pharmaceutical companies charge the public. In Asia, we may be seeing a push back against what some see as price-gouging of the most desperate and vulnerable segment of the world's population: The sick and the poor.

In the recent past, Nomadic Politics examined, in two posts, alleged price-gouging for one company's drug for Hepatitis C. There are further developments to that story. First, let's re-cap.

The Breakthrough

The story begins with some very good news. It was reported last year that one orally-administered drug,  Sovaldi (sofosbuvir), has proved to be a breakthrough for the treatment of a silent killer virus, hepatitis C.  

From the clinical trial reports, researchers claimed that Sovaldi was not a life-long treatment but a genuine cure for the deadly disease itself. The therapy required a 12-week therapy but at the end, most of the patients would be free of the disease.  

Then came the bad news: Gilead Sciences, the patent-owner and developer of the drug, was definitely not a charity organization. It was a profit-making company which, according to Wikipedia, earned US $12.059 billion in 2014. 

It was immediately clear to everybody that the Hep C cure was not going to be given away free. Few, however, were expecting the price the company settled on. Sovaldi costs $1,000 a day, adding up to staggering $84,000 for a 12-week supply. 

The problem is obvious: at that price, a cure is out of reach of most patients in the world and even in rich countries.

Drug Patent Extortion: Indian Court Defeats Corporate Greed in Hepatitis C Cure

by Nomad

An Indian court has thrown a monkey wrench in an American pharma's plan to reap exorbitant profits from its Hepatitis cure.

Last year, we reported about a breakthrough in the treatment of one from of Hepatitis C.

This orally-administered drug, Sovaldi (sofosbuvir), was, from the clinical trial reports, not a life-long treatment, like HIV drugs but a genuine cure for the disease itself. The therapy required a 12-week therapy but at the end, the patient would be free of the disease.

In 2012, when Bristol-Myers Squibb (BMS) announced the final trial results conducted with Gilead Sciences for the treatment of hepatitis C (HCV), the news seemed too good to be true. A 100% cure rate within 12 weeks. The possible side effects, such as, headache, fatigue, and nausea, were minor compared to other treatment drugs.
All good news? A victory for modern medical science, right?
Not quite.

According to a press release by Médecins Sans Frontières

The oral drug, which first received regulatory approval in the US in November 2013, and has been priced by Gilead at US$84,000 for a treatment course, or $1,000 per pill in the US, has caused a worldwide debate on the pricing of patented medicines. A study from Liverpool University showed that sofosbuvir could be produced for as little as $101 for a three-month treatment course.

Although the corporate decision was widely criticized at the time, the pharma companies seemed determined to put the profit margin at the top of its priority. Some say that decision was indefensible.

Challenge in Indian Court

According to one report, this example of what some see as corporate extortion has been challenged in Indian courts.  The Indian authorities have taken a strict approach to granting pharma exclusive patents in favor of generic production.  In a recent patent decision, the Patent Office Controller of India rejected the patent application by Gilead on the grounds- admittedly weak- that the drug was not unique.

Cure for Hepatitis C: The Politics and Profits behind a Breakthrough

by Nomad

A breakthrough in curing a silent killer, Hepatitis C, should mean that patients will have a new lease on life. But unless they are extraordinarily wealthy or they  live in a state that expanded Medicaid in the wake of the Affordable Care Act, these people will be at the mercy of the profit-driven free market. So for most of the uninsured or under-insured Americans, it will mean no cure at all.

Good News 

Even for researchers who are loathe to use the word "cure," there's no question that the news is very good,

The Denver Post is reporting of a breakthrough drug for hepatitis C in clinical trials at the University of Colorado Hospital. This new anti-viral is being called the blockbuster cure for patients who have long had to endure debilitating treatment for this liver-destroying disease.

Astoundingly, Sovaldi, a daily-dose pill manufactured by California-based Gilead Sciences Inc., has cured about 90 percent of patients in only 12 weeks when used with older drugs, studies nationwide have found.

In other words, it's a very nearly the cure for a killer. Not life-long treatment like the HIV drug therapy, but an actual eradication of the affliction. 

A big big deal.

Silent Killer of the Baby Boomers
This is a disease that infects an estimated 150–200 million people around the world. In the US the majority of the estimated 3.2 million people with chronic hepatitis C virus (HCV) are baby boomer adults. Seventy-three percent of hepatitis C deaths were reported among those 45 to 64 years old.
For every 100 people who contract the virus, 75 will develop chronic infection. About 5 to 20 will develop cirrhosis over the next 20 to 30 years. Between 1 and 5 will die of cirrhosis and liver cancer. Meaning, more than 350 000 people die every year from hepatitis C-related liver diseases. The disease is found worldwide with some countries having chronic infection rates as high as 5% and above.

One of the particularly dangerous aspects of the disease is its insidious nature. Most of those infected with the virus do not know that they have it, which means they could easily be spreading it to others via exposure to blood—or, occasionally, sexual contact. The main mode of transmission in countries with infection rates above 5% is attributed to unsafe injections using contaminated equipment.

"In almost every country it is a significant public health problem, points out Charles Gore, president of the World Hepatitis Alliance, "and, in some, such as Egypt, which has 10% to 15% of its population living with hepatitis C, and Vietnam, where the prevalence of hepatitis B is 15% to 20%, it is simply overwhelming."

So curing this disease is unquestionably a great triumph for science. It's something that the researchers should be proud of. 

There is however one problem.

Now...The Bad News

Sovaldi was approved by the Food and Drug Administration (FDA) last December, but it won't be cheap. Sovaldi costs $1,000 a day and that adds up to staggering $84,000 for a 12-week supply.